Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs: 1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.

Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.

Abstract: A robotic workstation includes apparatus for actuating one or more syringes. Each syringe has a cylinder and a plunger movable in the cylinder. A programmable robot has at least one syringe actuating device. The actuating device has a holder for holding and releasing a syringe cylinder and an actuator movable relative to the holder. A coupling couples the actuator to the plunger of the syringe such that, when the cylinder is held by the holder, movement of the actuator relative to the holder causes the plunger to move in the cylinder. A method of dispensing a material into a container includes robotically moving at least one syringe to a position for dispensing into a container. The plunger is robotically moved in the cylinder to dispense material from the syringe into the container. The workstation suitably includes a mixing apparatus for mixing materials in an array of containers at the workstation.

Abstract: A method is disclosed of synthesizing a crystalline material comprising a CHA framework type molecular sieve and having a composition involving the molar relationship: (n)X2O3:YO2, wherein X is a trivalent element; Y is a tetravalent element; and n is from 0 to less than 0.01. The method comprises preparing a reaction mixture capable of forming said material, said mixture comprising a source of water, a source of an oxide of a tetravalent element Y and optionally a source of an oxide of a trivalent element X, wherein the reaction mixture is substantially free of fluoride ions added as HF; maintaining the reaction mixture under conditions sufficient to form crystals of the crystalline material; and than recovering the crystalline material. The reaction mixture comprises either a specific directing agent for directing the formation of a CHA framework type molecular sieve and/or a H2O:YO2 molar ratio of greater than 20.

Abstract: The synthesis of a crystalline material, in particular, a high silica zeolite, comprising a chabazite-type framework molecular sieve is conducted in the presence of an organic directing agent having the formula: [R1R2R3N—R4]+Q? wherein R1 and R2 are independently selected from hydrocarbyl groups and hydroxy-substituted hydrocarbyl groups having from 1 to 3 carbon atoms, provided that R1 and R2 may be joined to form a nitrogen-containing heterocyclic structure, R3 is an alkyl group having 2 to 4 carbon atoms and R4 is selected from a 4- to 8-membered cycloalkyl group, optionally, substituted by 1 to 3 alkyl groups each having from 1 to 3 carbon atoms; and a 4- to 8-membered heterocyclic group having from 1 to 3 heteroatoms, said heterocyclic group being, optionally, substituted by 1 to 3 alkyl groups each having from 1 to 3 carbon atoms and the or each heteroatom in said heterocyclic group being selected from the group consisting of O, N, and S, or R3 and R4 are hydrocarbyl groups having from 1 to 3 carbon a

Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.

Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1–28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.

Abstract: A selective hydrogenation catalyst composition comprises a support; a first metal component comprising rhodium; and a second metal component comprising a metal other than rhodium and selected from Groups 1 to 15 of the Periodic Table of Elements, wherein said first and second components are predominantly contained in an outer surface layer of the support having a depth of not more than 1000 microns.

Abstract: A selective hydrogenation catalyst composition comprises a rhodium component present in an amount such that the catalyst composition comprises less than 3.0% of rhodium by weight of the total catalyst composition; and an indium component present in an amount such that the catalyst composition comprises at least 0.3% and less than 5.0% of indium by weight of the total catalyst composition.

Abstract: A selective hydrogenation catalyst composition comprises at least two different metal components selected from Groups 8 to 10 of the Periodic Table of Elements, one of which may be rhodium, and at least one metal component selected from Group 13 of the Periodic Table of Elements, such as indium.

Abstract: A crystalline material is described that has an AEI framework type, wherein the material, in its calcined, anhydrous form, has a composition involving the molar relationship: (n)X2O3:YO2, wherein X is a trivalent element, Y is a tetravalent element n is from 0 to less than 0.01. The material is normally synthesized in a halide, typically a fluoride, medium and exhibits activity and selectivity in the conversion of methanol to lower olefins, especially ethylene and propylene.

Abstract: The synthesis of a crystalline material, in particular a high silica zeolite, having a chabazite-type framework is aided by the addition to the synthesis mixture of seeds of an AEI framework-type material. The chabazite-type product has a relatively small crystal size and exhibits activity and selectivity in the conversion of methanol to lower olefins, especially ethylene and propylene.

Abstract: A crystalline material substantially free of framework phosphorus and comprising a CHA framework type molecular sieve with stacking faults or at least one intergrown phase of a CHA framework type molecular sieve and an AEI framework type molecular sieve, wherein said material, in its calcined, anhydrous form, has a composition involving the molar relationship: (n)X2O3:YO2, wherein X is a trivalent element; Y is a tetravalent element; and n is from 0 to about 0.5. The material exhibits activity and selectivity in the conversion of methanol to lower olefins, especially ethylene and propylene.

Abstract: An selective hydrogenation catalyst composition comprises a rhodium component present in an amount such that the catalyst composition comprises less than 3.0% of rhodium by weight of the total catalyst composition; and an indium component present in an amount such that the catalyst composition comprises at least 0.3% and less than 5.0% of indium by weight of the total catalyst composition.

Abstract: A selective hydrogenation catalyst composition comprises at least two different metal components selected from Groups 8 to 10 of the Periodic Table of Elements, one of which may be rhodium, and at least one metal component selected from Group 13 of the Periodic Table of Elements, such as indium.

Abstract: A selective hydrogenation catalyst composition comprises a support; a first metal component comprising rhodium; and a second metal component comprising a metal other than rhodium and selected from Groups 1 to 15 of the Periodic Table of Elements, wherein said first and second components are predominantly contained in an outer surface layer of the support having a depth of not more than 1000 microns.

Abstract: The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translation products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs:1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided.